Study shows new treatment may help postmenopausal women with osteoporosis
In women who stopped zoledronic acid after three years, BMD decreased significantly but remained well above baseline levels. Those who remained on zoledronic acid for six years reduced their risk for new spine fractures by 52 percent compared with those who stopped treatment at three years.
In both groups, bone markers were maintained over six years within the normal postmenopausal range. In patients who discontinued zoledronic acid after three years, there was no evidence of accelerated bone loss.
The long-term study, which extended the Health Outcomes and Reduced Incidence with Zoledronic Acid Once Yearly Pivotal Fracture Trial by three years, is designed to evaluate the long-term efficacy and safety of the drug for postmenopausal osteoporosis. After three years, women were randomly assigned to zoledronic acid infusion or annual placebo infusion for three additional years.
Last updated on 10/26/2010